TABLE 4.
Study of key non-HLA antibodies in a second, external cohort
| Antibody name | Antigen specificity | Antibody levels | Differential levels analysis | |||
|---|---|---|---|---|---|---|
| At diagnosis | AMR/mixed vs ACR | AMR/mixed vs control | ||||
| ACR, median (IQR) | AMR/mixed, median (IQR) | Control, median (IQR) | P | P | ||
| IgG Ro/SS-A (52 kDa) | Ro/SS-A (52 kDa) | 383 (129–740.5) | 9002 (1714–10527) | 228 (0–652) | 0.0041 | 0.0022 |
| IgG La/SS-B | La/SS-B | 282 (0–492) | 557 (551–748) | 206 (0–506) | 0.0299 | 0.0094 |
| IgG CENP-B | Major centromere autoantigen B | 240 (0–539) | 440 (411–828) | 0 (0–554) | 0.1367 | 0.087 |
| IgG PDH | PDH | 0 (0–0) | 292 (0–339) | 0 (0–0) | 0.0082 | 0.0664 |
| IgM Ro/SS-A (52 kDa) | Ro/SS-A (52 kDa) | 404 (116–793.5) | 304 (236–330) | 224 (0–557) | 0.6264 | 0.2983 |
| IgM La/SS-B | La/SS-B | 0 (0–327) | 254 (0–380) | 0 (0–326) | 0.2310 | 0.2111 |
| IgM CENP-B | Major centromere autoantigen B | 266 (0–476.5) | 972 (646–1404) | 200 (0–330) | 0.0289 | 0.0267 |
| IgM PDH | PDH | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.4134 | 0.3011 |
The levels of IgG and IgM non-HLA antibodies significantly increased at diagnosis in AMR/mixed rejection in the discovery cohort (UHN, Toronto) were interrogated in a second, independent cohort (CHUM, Montreal). P < 0.05 was considered significant.
ACR, acute cellular rejection; AMR, antibody-mediated rejection; HLA, human leukocyte antigen; Ig, immunoglobulin; IQR, interquartile range.